The Report

Deep dives into company funding, growth strategies, and market insights from the world's most innovative businesses

7 reports and counting

Updated daily with latest market intelligence
Fundraising
Ginkgo Bioworks

Ginkgo Bioworks Raises $350M in Series E

Ginkgo Bioworks, a Biotech company based in 27 Drydock Avenue, Boston, MA 02210, has raised $350M in Series E at a $4.9B valuation led by Baillie Gifford, General Atlantic, Cascade Investment, T. Rowe Price, Viking Global Investors.

Fundraising News Team
Nov 11, 2024
2 min read
Biotech
Ginkgo Bioworks

Ginkgo Bioworks raises $1.5B PIPE at $15B valuation

Ginkgo Bioworks raises $1.5B in PIPE at $15B valuation. Synthetic biology and organism engineering platform...

Editorial Team
Sep 20, 2024
1 min read$1.5B
Biotech
Ginkgo Bioworks

Ginkgo Bioworks raises $350M Series E at $4.9B valuation

Ginkgo Bioworks raises $350M in Series E at $4.9B valuation. Synthetic biology and organism engineering...

Editorial Team
Sep 15, 2020
1 min read$350M
Synthetic Biology
Ginkgo Bioworks

Ginkgo Bioworks transforms synthetic biology industry with $350M IPO at $15B valuation

Ginkgo Bioworks achieves $15B valuation through $350M IPO funding, establishing dominance in the synthetic biology market with innovative synthetic biology platform for organism design and manufacturing.

Michael Chang
Sep 3, 2025
8 min read$350M
Biotechnology
Ginkgo Bioworks

Ginkgo Bioworks Headquarters - Office Location & Address

Discover Ginkgo Bioworks's headquarters at 27 Drydock Ave, Boston, MA 02210. Synthetic biology company. Learn about the office facilities and work environment.

Editorial Team
Oct 5, 2025
2 min read
FoodTech
Umami Bioworks

Umami Bioworks Headquarters - Office Location & Address

Discover Umami Bioworks's headquarters at 61 Science Park Rd, Singapore, 117525. Cell-cultured seafood production. Learn about the office facilities and work environment.

Editorial Team
Oct 5, 2025
2 min read
Synthetic Biology
BioSynthetic Materials

BioSynthetic Materials Raises $720M Series D for Revolutionary Synthetic Biology Technology

BioSynthetic Materials secures $720M in Series D funding at $10.8B valuation to pioneer breakthrough synthetic biology technology.

Editorial Team
Sep 10, 2025
2 min read$720M
Page 1

Showing 7 reports • Page 1 • Category: all

Stay ahead of the market

Get weekly insights delivered to your inbox. No spam, just intelligence.